Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eletriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 0.98 |
| ▸ | HTR1D known ✓ | P28221 | 6/20 | 0.65 |
| ▸ | HTR1F known ✓ | P30939 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | HTR6 | P50406 | 15/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eletriptan SCHEMBL4431798 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL317370 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29984875 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL3713443 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL2146547 | 0.99 | HTR1B (0.96) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL798473 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29414096 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL26719 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL1556539 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL10083479 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105175397-B | A kind of hydrobromic acid eletriptan synthetic method | 上海现代哈森（商丘）药业有限公司 | 2017-10-10 | — | — | CN | disclosed |
| CN-104230895-B | Preparation method for eletriptan intermediate | 上海医药工业研究院 | 2017-02-08 | — | — | CN | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| EP-2093224-A1 | Process for preparing eletriptan hydrobromide form beta | Plus Chemicals B.V. (NL) | 2009-08-26 | — | — | EP | disclosed |
| EP-2093225-A1 | Process for preparing crystalline eletriptan hydrobromide form ß | Plus Chemicals B.V. (NL) | 2009-08-26 | — | — | EP | disclosed |
| US-20080287519-A1 | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide | PLUS CHEMICALS, B.V. (NL) | 2008-11-20 | — | — | US | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HTR1B 260/4885HTR1D 944/4885HTR1F 1354/4885 |
| US-20080287519-A1 | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide | TPSAB1, TPSD1, TPSB2 | HTR1B 604/4885HTR1D 669/4885HTR1F 1106/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HTR1B 260/4885HTR1D 944/4885HTR1F 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.